147 related articles for article (PubMed ID: 37789645)
1. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment.
Carreira LD; Oliveira RI; Moreira VM; Salvador JAR
Expert Opin Ther Targets; 2023; 27(11):1043-1058. PubMed ID: 37789645
[TBL] [Abstract][Full Text] [Related]
2. USP7: Target Validation and Drug Discovery for Cancer Therapy.
Zhou J; Wang J; Chen C; Yuan H; Wen X; Sun H
Med Chem; 2018; 14(1):3-18. PubMed ID: 29065837
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.
Colland F; Formstecher E; Jacq X; Reverdy C; Planquette C; Conrath S; Trouplin V; Bianchi J; Aushev VN; Camonis J; Calabrese A; Borg-Capra C; Sippl W; Collura V; Boissy G; Rain JC; Guedat P; Delansorne R; Daviet L
Mol Cancer Ther; 2009 Aug; 8(8):2286-95. PubMed ID: 19671755
[TBL] [Abstract][Full Text] [Related]
4. A patent review of ubiquitin-specific protease 7 (USP7) inhibitors (2014-present).
Li P; Liu Y; Liu HM
Expert Opin Ther Pat; 2022 Jul; 32(7):753-767. PubMed ID: 35343357
[TBL] [Abstract][Full Text] [Related]
5. The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy.
Nininahazwe L; Liu B; He C; Zhang H; Chen ZS
Drug Discov Today; 2021 Feb; 26(2):490-502. PubMed ID: 33157193
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
Chen C; Song J; Wang J; Xu C; Chen C; Gu W; Sun H; Wen X
Bioorg Med Chem Lett; 2017 Feb; 27(4):845-849. PubMed ID: 28108249
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-specific peptidase 7 (USP7) and USP10 mediate deubiquitination of human NHE3 regulating its expression and activity.
Han Y; Yun CC
FASEB J; 2020 Dec; 34(12):16476-16488. PubMed ID: 33095475
[TBL] [Abstract][Full Text] [Related]
9. Dissenting degradation: Deubiquitinases in cell cycle and cancer.
Bonacci T; Emanuele MJ
Semin Cancer Biol; 2020 Dec; 67(Pt 2):145-158. PubMed ID: 32201366
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Potent and Selective Degrader for USP7.
Pei Y; Fu J; Shi Y; Zhang M; Luo G; Luo X; Song N; Mi T; Yang Y; Li J; Zhou Y; Zhou B
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202204395. PubMed ID: 35691827
[TBL] [Abstract][Full Text] [Related]
11. Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease.
Rawat R; Starczynowski DT; Ntziachristos P
Curr Opin Cell Biol; 2019 Jun; 58():85-94. PubMed ID: 30897496
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.
Chen H; Zhu X; Sun R; Ma P; Zhang E; Wang Z; Fan Y; Zhou G; Mao R
Invest New Drugs; 2020 Dec; 38(6):1707-1716. PubMed ID: 32468271
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 7 is a regulator of ubiquitin-conjugating enzyme UbE2E1.
Sarkari F; Wheaton K; La Delfa A; Mohamed M; Shaikh F; Khatun R; Arrowsmith CH; Frappier L; Saridakis V; Sheng Y
J Biol Chem; 2013 Jun; 288(23):16975-16985. PubMed ID: 23603909
[TBL] [Abstract][Full Text] [Related]
14. Highlights in USP7 inhibitors for cancer treatment.
Oliveira RI; Guedes RA; Salvador JAR
Front Chem; 2022; 10():1005727. PubMed ID: 36186590
[TBL] [Abstract][Full Text] [Related]
15. (1)H, (13)C and (15)N backbone resonance assignment for the 40.5 kDa catalytic domain of Ubiquitin Specific Protease 7 (USP7).
Di Lello P; Rougé L; Pan B; Maurer T
Biomol NMR Assign; 2016 Oct; 10(2):345-9. PubMed ID: 27386854
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Li P; Liu HM
Eur J Med Chem; 2020 Apr; 191():112107. PubMed ID: 32092586
[TBL] [Abstract][Full Text] [Related]
17. Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.
Zhang W; Sartori MA; Makhnevych T; Federowicz KE; Dong X; Liu L; Nim S; Dong A; Yang J; Li Y; Haddad D; Ernst A; Heerding D; Tong Y; Moffat J; Sidhu SS
J Mol Biol; 2017 Nov; 429(22):3546-3560. PubMed ID: 28587923
[TBL] [Abstract][Full Text] [Related]
18. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
[TBL] [Abstract][Full Text] [Related]
19. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy C; Conrath S; Lopez R; Planquette C; Atmanene C; Collura V; Harpon J; Battaglia V; Vivat V; Sippl W; Colland F
Chem Biol; 2012 Apr; 19(4):467-77. PubMed ID: 22520753
[TBL] [Abstract][Full Text] [Related]
20. Targeting the deubiquitinase USP7 for degradation with PROTACs.
Murgai A; Sosič I; Gobec M; Lemnitzer P; Proj M; Wittenburg S; Voget R; Gütschow M; Krönke J; Steinebach C
Chem Commun (Camb); 2022 Aug; 58(63):8858-8861. PubMed ID: 35852517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
